A Prospective and Retrospective Observational/Non-interventional Study to Characterize Biomarkers and Disease Progression in Patients With MECP2 Duplication Syndrome
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 29
- 试验地点
- 6
- 主要终点
- Change From Baseline in the Frequency of Seizures
研究概览
简要总结
The purpose of the study is to prospectively assess longitudinal changes in biomarkers (MECP2, potential biomarkers of target engagement and disease activity) in cerebrospinal fluid (CSF) and blood; characterize longitudinal changes in performance on clinical scales (clinician-reported measures of neurodevelopment and functioning) and caregiver-reported outcome assessments (communication, gastrointestinal, social-emotional-adaptive behavioral measures); evaluate longitudinal changes in caregiver-reported health-related quality-of-life measures; and assess the frequency, type, and severity of seizures over time.
详细描述
This is a multi-center, non-randomized, non-interventional prospective and retrospective study in up to 40 participants with MECP2 duplication syndrome (MDS) who can undergo general anesthesia or conscious sedation to collect fluid biomarkers (CSF and blood), undergo electrophysiological assessments (electroencephalogram [EEG], evoked potentials [EP], pupillometry), clinical assessments and caregiver reported outcomes measures, to be used in support of the development of therapies for MDS. The study duration for each participant will be approximately 110 weeks.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 1 Month 至 65 Years（Child, Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participant has a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication)
- •Participant has a parent or caregiver (CG) ≥ 18 years old capable of providing informed consent (signed and dated), and able to attend all scheduled study visits and provide feedback regarding the participant's symptoms and performance as described in the protocol and be able to comply with all study requirements and activities
- •Male ≥ 1 month and ≤ 65 years of age
- •No contraindications for lumbar puncture (LP)'s, blood draws, sedation (if necessary) or other study activities
- •Medically stable to complete the study and will tolerate sedation or general anesthesia and other study activities
排除标准
- •Clinically significant abnormalities in medical history (e.g., clinically significant renal, hepatic, or cardiac abnormalities; major surgery within 3 months of screening) or upon physical examination that could potentially impact the NH of MDS
- •Unwillingness or inability to comply with study procedures, including follow up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator
- •Treatment with an investigational drug, gene therapy, stem cell therapy, biological agent, or device within 30 days of screening, or 5 half-lives of investigational agent, whichever is longer (participants cannot be concurrently enrolled in NH00006 and ION440-CS1).
研究组 & 干预措施
MECP2 Duplication Syndrome Disease Participants
Participants with a diagnosis of MDS with genetic confirmation of MECP2 duplication (or triplication) will undergo CSF and blood collection, electrophysiological and clinical assessments, up to Week 104 as a part of prospective study. Each participant's medical and family history data will be collected retrospectively from available medical notes and charts, from birth up to the end of the study (up to 110 weeks). Participants will have an option to participate in an optional sub-study that will capture pre-defined list of activities at home video.
结局指标
主要结局
Change From Baseline in the Frequency of Seizures
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in Observer Reported Communication Ability Measure
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in MeCP2 in the CSF
时间窗: Baseline and on Weeks 13, 26, 39, 52
Change From Baseline in Vineland Adaptive Behavior Scales 3rd Edition
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in Global Assessment of Severity of Epilepsy Scale Score
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in Quality-of-Life Inventory-Disability Score
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Laboratory biomarkers for MECP2 Duplication
时间窗: Baseline and on Weeks 13, 26, 39, 52
Proteomic analysis of plasma samples to determine biomarkers of disease progression.
Change From Baseline in MECP2 Duplication Syndrome Severity Scale Across All Domains
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in the Revised Motor Behavioral Assessment
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
Change From Baseline in the Bayley Scales of Infant and Toddler Development, 3rd Edition
时间窗: Baseline and on Weeks 13, 26, 39, 52, 78, 104
次要结局
- Change From Baseline in Auditory Evoked Potential(Baseline and on Weeks 13, 26, 39, 52, 78, 104)
- Perform a retrospective chart review of the participant's medical history and family history to characterize the natural history of MDS(Baseline and on Weeks 13, 26, 39, 52, 78, 104)
- Change From Baseline in Visual Evoked Potentials(Baseline and on Weeks 13, 26, 39, 52, 78, 104)